An At-Home Ketamine Company Just Asked Congress for a 500-Veteran VA Pilot
A House subcommittee held a hearing on psychedelic therapies for veterans on November 18. The VA’s written testimony does not mention ketamine once.
The most detailed ketamine proposal in the hearing record came from Mindbloom, an at-home telehealth provider. It asked the subcommittee to urge a VA pilot of at-home ketamine for 500 rural veterans.
For an in-clinic practice that treats veterans, three things in that record matter. A competitor made its cost and access case to Congress. A senior member said the VA needs entry criteria for outside providers. And nobody filed the case for supervised in-clinic care.
HealingMaps GPO members save 40 percent or more on medical supplies and 15 to 20 percent on malpractice insurance. Joining is free. It is the first GPO built for the ketamine industry. Members also get 20 to 30 percent off HIPAA compliant payment processing and discounted LegitScript certification, with no obligation. See how much your clinic can save →
| Key Takeaway | Detail |
|---|---|
| What happened | House Veterans’ Affairs health subcommittee hearing, November 18, on psychedelic-assisted therapies for veterans |
| The VA’s testimony | 21 active psychedelic studies and 10 facilities chosen as early implementers. Ketamine is not mentioned |
| The ketamine ask | Mindbloom asked for a VA pilot of at-home ketamine for 500 rural veterans with treatment-resistant depression |
| The prices it filed | $170 per at-home treatment, against $500 for in-clinic IV ketamine and $1,500 for Spravato, by its own estimates |
| The gate to watch | The ranking member said the VA must set criteria for any provider joining its community care network |
| Who leads treatment | The American Psychiatric Association told the panel a psychiatrist should lead care for psychiatric indications |
| What is missing | As of November 19, no ketamine clinic or clinic association appears among the witnesses or posted statements |
What the VA said, and what it left out
The VA’s witness was Andrew Gradison, senior advisor to the under secretary for health. His written statement runs five pages.
It says the VA is running 21 active studies of psychedelic treatments, covering MDMA, psilocybin, DMT and LSD. It says the department has picked 10 facilities to serve as early implementers, educators or sites in training. And it says the VA intends to be the first health system in the country to deliver these treatments once they are approved.
The statement does not use the word ketamine, and it does not address community care. The one treatment in this space the VA already provides went unmentioned by the VA.
Mindbloom’s letter fills in that gap from the outside. It says the VA offers ketamine or esketamine at roughly 50 sites, citing Senate testimony from 2025.
The at-home pitch that is now in the record
Mindbloom’s statement for the record is dated November 13. The company says it has delivered 900,000 at-home treatments across 39 states since 2019, including for more than 3,000 veterans. Those are its own figures.
The ask is specific. A VA pilot of telehealth-supported, at-home ketamine for 500 rural veterans with treatment-resistant depression. Twelve sessions each, at about one million dollars in treatment costs. The letter says it would need no new law, funding or scheduling action.
It also filed a price comparison, which is the part a clinic owner should read closely.
| Treatment | Cost per treatment | Annual cost per patient |
|---|---|---|
| Mindbloom, at home | $170 | $4,420 for 26 sessions |
| IV ketamine, in clinic | $500 | $13,000 for 26 sessions |
| Spravato | $1,500 | $39,000 for 26 sessions |
| COMP360 psilocybin, projected | Not given | $50,000 to $65,000 for 2 to 4 sessions |
Every number in that table is the company’s estimate. The $500 figure for in-clinic IV ketamine is now sitting in a congressional record as the expensive option.
The Special Forces Foundation backed the request in its own statement. It says it funded at-home ketamine for 20 Green Beret veterans through Mindbloom. It also says veterans it supports report waiting more than six months to start ketamine at the VA.
Mindbloom cites a study of 1,325 veterans that is still under peer review. The letter itself says its evidence is observational, largely patient reported, and drawn from people who chose and paid for treatment.
The gate is community care
The warning about private providers came from the top Democrat on the panel. According to Marijuana Moment, Rep. Julia Brownley said the arrival of psychedelics will likely grow an industry of wellness centers marketing themselves to veterans. Her example was ketamine prescribed off label for depression.
She said it will be critical for the VA to develop criteria for any provider of these treatments to join its community care network. That network is how a veteran gets referred to an outside clinic at VA expense.
The other filings point the same direction. The Veterans of Foreign Wars wrote that community care should supplement the VA, not replace it. The American Psychiatric Association wrote that for depression, PTSD and other psychiatric indications, treatment should be led by a psychiatrist.
Mindbloom’s letter is written for that gate. It says a pilot would let the VA address access gaps through community care providers who meet VA criteria.
One witness put ketamine and psilocybin side by side
Dr. Mark Niciu of the University of Iowa described ketamine to the panel as a non-traditional psychedelic. His team uses it as the comparison drug in a psilocybin trial for heavy drinking.
In the pilot, 10 men received either psilocybin or ketamine with therapy. Participants guessed which drug they got at the rate of a coin flip. The ketamine group went from 21.8 drinks a week to 7.0.
Ten people is a pilot, not a result. It is still a congressional witness treating ketamine as a peer of psilocybin, which is how the field’s own definitions have started to read.
What an in-clinic practice can do with this
Know the numbers being used. If a referral coordinator or a veteran quotes $170 against $500, the answer is what the difference buys. A clinician in the room, monitoring, and someone to respond.
Get ready for criteria. If the VA writes entry rules for community care, they will ask for documentation. Screening, monitoring, staffing and outcomes are the things to have on paper now.
Show up in the record. Veterans groups, a telehealth company and two professional associations filed statements. Supervised ketamine clinics did not. That is a choice the field can make differently next time.
We covered the VA’s own psilocybin study when it started a Phase 3 trial in August, and the push for federal standards when two members of Congress named what they want regulated. Veterans can read our guide to qualifying for ketamine treatment at the VA.
Patients comparing supervised options can start with our directory of verified ketamine clinics.
This article is for informational purposes and is not legal, medical or business advice. Figures attributed to Mindbloom and the Special Forces Foundation are their own claims from statements filed with the subcommittee and have not been independently verified.
